Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Operating income | -$20.8M | -$21.0M | -$14.6M | -$7.77M | -$20.1M | -$30.4M | -$45.5M | -$48.4M | -$19.3M | -$4.16M |
| Net income | -$17.0M | -$14.9M | -$9.45M | -$7.04M | -$20.4M | -$32.7M | -$42.2M | -$48.9M | -$13.2M | -$8.28M |
| EPS (diluted) | -$0.63 | -$2.41 | -$1.39 | -$6.11 | -$2.10 | -$0.47 | -$11.90 | -$616.07 | -$107.35 | -$0.88 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.6M | -$19.2M | -$15.6M | -$7.57M | -$16.2M | -$31.2M | -$35.0M | -$40.9M | -$18.2M | -$3.27M |
| Capital expenditures | $6.60K | $14.7K | — | $51.5K | $88.0K | $130K | $16.3K | $14.3K | — | — |
| Free cash flow | -$16.6M | -$19.2M | — | -$7.62M | -$16.3M | -$31.4M | -$35.0M | -$40.9M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.40M | $5.95M | $2.83M | $13.9M | $40.7M | $91.3M | $51.2M | $14.8M | $406K | $1.83M |
| Total assets | $13.1M | $11.3M | $8.19M | $20.6M | $48.6M | $104M | $60.2M | $18.1M | $1.61M | $3.07M |
| Total liabilities | $11.8M | $7.55M | $6.21M | $4.99M | $8.12M | $10.6M | $10.4M | $10.8M | $3.48M | $402K |
| Shareholders' equity | $1.32M | $3.70M | $1.72M | $15.6M | $40.5M | $93.0M | $49.9M | $7.28M | -$1.86M | $2.67M |
| Retained earnings | -$44.6M | -$67.0M | -$76.7M | -$83.8M | -$104M | -$134M | -$176M | -$225M | -$238M | -$246M |
| Shares (wtd avg diluted) | 27.1M | 7.29M | 12.9M | 2.04M | 9.68M | 70.3M | 3.81M | 79.4B | 123K | 9.41M |
Every figure is extracted from Hepion Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.